A naukri.com initiative
Bioengineer
1d
127
Image Credit: Bioengineer
Scientists Discover Crucial Enzyme Target to Combat Aggressive Brain Cancers
- Researchers at The Ohio State University have identified the metabolic target PGM3 as a potential strategy to combat aggressive brain cancers like glioblastoma.
- PGM3 plays a crucial role in the hexosamine biosynthesis pathway, influencing glycosylation processes essential for tumor growth and survival.
- Targeting PGM3 disrupts glycosylation support systems in tumor cells, hindering their growth on a cellular and molecular level.
- Inhibition of PGM3 leads to the collapse of glycosylation pathways, impacting membrane stability and proliferative signaling in glioblastoma cells.
- The study's findings reveal a metabolic feedback loop involving SREBP-1, disrupting fatty acid synthesis and impeding tumor growth when PGM3 is targeted.
- Collaborative efforts with international scientists validate the efficacy of PGM3 inhibition across diverse cellular contexts in glioblastoma.
- The research suggests that pharmaceutical targeting of PGM3 could yield novel antitumor agents, enhancing current treatment approaches.
- This groundbreaking study underscores the importance of metabolic reprogramming in cancer survival and offers fresh insights into glioblastoma treatment.
- The identification of PGM3 as a metabolic vulnerability presents a potential shift towards more effective, targeted therapies for brain tumors and beyond.
- Future studies will assess the efficacy of PGM3 inhibitors in vivo, with the aim of revolutionizing cancer treatment strategies with a focus on metabolic vulnerabilities.
Read Full Article
7 Likes
For uninterrupted reading, download the app